ProMIS Neurosciences reports preliminary safety data for amyloid-clearing Alzheimer's candidate

ProMIS Neurosciences has released early-stage trial data for a novel amyloid-clearing drug candidate aimed at reducing side effects associated with current Alzheimer's therapies. While the preliminary results suggest a potential safety improvement, the efficacy and long-term clinical outcomes remain unproven in larger cohorts.